-
公开(公告)号：EP0717849B1
公开(公告)日：1998-05-20
申请号：EP94926697.7
申请日：1994-09-09
IPC分类号： G01N33/68 , G01N33/566 , G01N33/94
CPC分类号： C07K14/715 , A61K49/0004 , C07K16/40 , G01N33/566 , G01N33/6863 , G01N2500/00
摘要： The present invention provides for a stable, biologically active CNTF/receptor complex, and hybrids or mutants thereof. The invention is also based in part on the discovery that the CNTF/receptor complex promotes diferentiation through a signal transduction pathway on target cells that do not express the CNTF receptor. The invention further provides for a specific CNTFR mutant that promotes signal transduction without binding CNTF. The invention also provides for a CNTF/receptor blocking mutant, a mutant possessing a high binding affinity to CNTF, but possessing no signal transducing function. The present invention also identifies receptor components shared by the IL-6, CNTF, LIF and OSM signal transduction pathways, and the assay systems based on the use of such components.
-
公开(公告)号：EP0726954A1
公开(公告)日：1996-08-21
申请号：EP94930818.0
申请日：1994-10-19
CPC分类号： C07K14/715 , A61K38/00 , C07K14/475 , C07K14/5412
摘要： Heterodimer proteins comprising a soluble α specificity determining cytokine receptor component and the extracellular domain of a β receptor component function as CNTF and IL-6 antagonists.
摘要翻译： 包含可溶性α特异性决定细胞因子受体组分和β受体组分的胞外结构域的异二聚体蛋白质起CNTF和IL-6拮抗剂的作用。
-
公开(公告)号：EP0717849A1
公开(公告)日：1996-06-26
申请号：EP94926697.0
申请日：1994-09-09
CPC分类号： C07K14/715 , A61K49/0004 , C07K16/40 , G01N33/566 , G01N33/6863 , G01N2500/00
摘要： The present invention provides for a stable, biologically active CNTF/receptor complex, and hybrids or mutants thereof. The invention is also based in part on the discovery that the CNTF/receptor complex promotes diferentiation through a signal transduction pathway on target cells that do not express the CNTF receptor. The invention further provides for a specific CNTFR mutant that promotes signal transduction without binding CNTF. The invention also provides for a CNTF/receptor blocking mutant, a mutant possessing a high binding affinity to CNTF, but possessing no signal transducing function. The present invention also identifies receptor components shared by the IL-6, CNTF, LIF and OSM signal transduction pathways, and the assay systems based on the use of such components.
-
公开(公告)号：EP0651809A1
公开(公告)日：1995-05-10
申请号：EP91912876.0
申请日：1991-06-03
发明人： BOULTON, Teri, G. , COBB, Melanie, H. , YANCOPOULOS, George, D. , NYE, Steven , PANAYOTATOS, Nikos
CPC分类号： G01N33/5041 , C12N9/12 , C12Q1/485 , G01N33/5008 , G01N33/573 , G01N2333/9121 , G01N2500/00
摘要： The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides fore recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity. These methods may be extremely useful in screening compounds for the presence of a desired cellular factor activity. In specific embodiments, compounds which may be useful in the treatment of Alzheimer's disease , peripheral neuropathies, and diabetes may be identified using the methods of the invention.
-
公开(公告)号：EP4248740A2
公开(公告)日：2023-09-27
申请号：EP23175415.1
申请日：2016-04-12
申请人： Regeneron Pharmaceuticals, Inc. , Yale University , Institute for Research in Biomedicine (IRB)
发明人： HERNDLER-BRANDSTETTER, Dietmar , FLAVELL, Richard A. , FRLETA, Davor , GURER, Cagan , MANZ, Markus, Gabriel , MURPHY, Andrew, J. , PALM, Noah, W. , SHAN, Liang , STEVENS, Sean , STROWIG, Till , YANCOPOULOS, George, D. , DE ZOETE, Marcel
IPC分类号： A01K39/00
摘要： Genetically modified non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome are provided. Also provided are methods for making non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome, and methods for using non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human T cell and/or natural killer (NK) cell development and function, in modeling human pathogen infection of human T cells and/or NK cells, and in various in vivo screens.
-
公开(公告)号：EP3898695A1
公开(公告)日：2021-10-27
申请号：EP19839545.1
申请日：2019-12-18
-
公开(公告)号：EP3897715A1
公开(公告)日：2021-10-27
申请号：EP19839551.9
申请日：2019-12-18
发明人： MURPHY, Andrew, J. , SKOKOS, Dimitris , WAITE, Janelle , ULLMAN, Erica , HERMANN, Aynur , SMITH, Eric , OLSON, Kara , WEI, Joyce , YANCOPOULOS, George, D.
IPC分类号： A61K39/395 , A61P35/02 , C07K16/28 , C07K16/30
-
公开(公告)号：EP3558347A1
公开(公告)日：2019-10-30
申请号：EP17829806.3
申请日：2017-12-15
-
公开(公告)号：EP2986739B1
公开(公告)日：2018-04-04
申请号：EP14784689.3
申请日：2014-04-15
发明人： FRENDEWEY, David , DROGUETT, Gustavo , KOSS, Matthew , THURSTON, Gavin , YANCOPOULOS, George, D.
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Q2600/178
摘要： Compositions and methods for determining circulating biomolecules before, during, and/or after treatment of a patient with an anti-cancer or anti-tumor drug (or putative drug) are described. Methods of treatments based on the compositions and methods described herein are also provided. Noninvasive methods and kits are provided for assessing the efficacy of an anti-cancer therapy for killing or damaging cancer cells. Embodiments are used to determine the cancer-killing efficacy of an anti-cancer drug in a patient, to optimize the selection of an anti-cancer drug for treatment of a patient, to adjust the dosage of an anti-cancer drug for treatment of a particular cancer in a patient and for identifying useful anti-cancer therapeutics for any one particular type of cancer.
-
公开(公告)号：EP1833847B1
公开(公告)日：2011-07-20
申请号：EP06717668.5
申请日：2006-01-06
CPC分类号： C07K14/65 , A61K38/30 , C07K2319/00 , C07K2319/30 , C07K2319/75
摘要： A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.02 秒)
